Brickell Biotech
Brickell Biotech is focused on the acquisition, development, and commercialization of drug therapies for the treatment of skin diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€36—55m (Dealroom.co estimates Feb 2015.)
Boulder Colorado (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $6.2m | Series A | |
$7.0m | Series B | ||
| N/A | $2.2m | Debt | |
| N/A | $10.0m | Series C | |
* | N/A | $15.0m | Debt |
| N/A | N/A | IPO | |
| N/A | $8.1m | Post IPO Equity | |
| Total Funding | €21.1m | ||
Related Content
Recent News about Brickell Biotech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.